Summary

The radiation dose management market is projected to reach USD 0.96 billion by 2031 from USD 0.51 billion in 2026, at a CAGR of 13.3% from 2026 to 2031. The market is experiencing steady growth owing to the increasing utilization of medical imaging procedures, rising focus on patient radiation safety, regulatory emphasis on radiation dose monitoring and optimization, and growing adoption of automated dose management systems. The increasing volume and complexity of imaging procedures are accelerating the use of RDM systems across hospitals, healthcare systems, diagnostic and imaging centers, and other imaging facilities. These systems enable healthcare organizations to collect, monitor, archive, analyze, and share patient radiation dose data; identify dose variations; compare radiation exposure across facilities and procedures; support diagnostic reference levels (DRLs); and optimize imaging practices. By offering, solutions accounted for the dominant share of the radiation dose management market in 2025. Based on offering, the radiation dose management market is segmented into solutions and services. The solutions segment accounted for the dominant share of the market in 2025, driven by the increasing adoption of software platforms that automate radiation-dose data collection, monitoring, analysis, reporting, benchmarking, and optimization across medical imaging environments. RDM solutions enable healthcare organizations to collect and analyze dose information from multiple imaging modalities, identify dose variations and outliers, compare radiation exposure against diagnostic reference levels (DRLs), and support imaging-protocol optimization. The solutions segment is also benefiting from the shift from standalone dose-tracking tools toward integrated and interoperable dose-management platforms that connect imaging modalities with PACS, RIS, hospital information systems, and other healthcare IT infrastructure. The continued adoption of automated alerts, dose analytics, patient dose tracking, and advanced optimization capabilities is expected to support demand for RDM solutions throughout the forecast period. By deployment model, the cloud-based deployment is expected to witness high growth during the forecast period. Based on deployment model, the radiation dose management market is segmented into on-premises and cloud-based/web-based deployment. The cloud-based/web-based deployment segment is expected to register higher CAGR during the forecast period, supported by the increasing need for centralized and remotely accessible dose-management systems across hospitals, diagnostic and imaging centers, and multi-site healthcare networks. Cloud-based and web-based RDM platforms allow healthcare organizations to access dose information across facilities, support centralized monitoring and benchmarking, and reduce the need for extensive on-site infrastructure. The adoption of these deployment models is further supported by the growing need to integrate dose data with PACS, RIS, and other healthcare information systems. North America accounted for the largest share of the radiation dose management market in 2025. The radiation dose management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the market in 2025, supported by well-established healthcare infrastructure, high adoption of advanced medical imaging technologies, large imaging volumes, and increasing emphasis on radiation safety and dose optimization. The US and Canada have mature healthcare systems with widespread use of CT, fluoroscopy, and interventional imaging, radiography, mammography, and nuclear medicine, creating strong demand for technologies that monitor and manage radiation exposure. Healthcare organizations across the region are increasingly adopting RDM solutions to automate dose monitoring, identify dose variations, benchmark radiation exposure, and support imaging protocol optimization. The presence of established RDM providers and a mature healthcare IT ecosystem further supports adoption of dose management technologies across hospitals, healthcare systems, and diagnostic imaging facilities. The continued expansion of advanced imaging and growing focus on patient safety and efficient dose management are expected to sustain North America's leading position in the RDM market during the forecast period. The breakdown of primary interview participants is as mentioned below: ・ By Company Type: Tier 1 - 45%, Tier 2 - 35%, and Tier 3 - 20% ・ By Designation: C-level Executives - 26%, Directors - 17%, and Others - 57% ・ By Region: North America - 40%, Europe - 20%, Asia Pacific - 30%, Latin America- 6%, and Middle East – 4% Bayer AG (Germany) and GE HealthCare (US) are among the key players in the radiation dose management market. ・ The study includes an in-depth competitive analysis of these key players in the radiation dose management market, with their company profiles, recent developments, and key market strategies. Research Coverage The report analyzes the radiation dose management market. It aims to estimate the market size and future growth potential of various market segments based on offering, function, technology, deployment model, revenue model, modality, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies. Reasons to buy this report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the radiation dose management market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights into the following pointers: ・ Analysis of key drivers (increasing utilization and complexity of imaging procedures, increasing regulatory emphasis on dose monitoring, optimization, and reference levels, growing concerns regarding radiation exposure and dose optimization), restraints (high implementation, integration, and maintenance costs, shortage of skilled professionals for radiation dose management and optimization), opportunities (increasing adoption of AI-enabled radiation dose optimization, growing adoption of vendor-neutral and cloud-based dose management platforms, increasing focus on age-specific radiation dose optimization), and challenges (lack of standardized and interoperable dose data across modalities and systems, variability in dose benchmarks and imaging protocols across institutions) influencing the growth of the radiation dose management market ・ Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product & service launches in the radiation dose management market ・ Market Development: Comprehensive information about lucrative markets (the report analyzes the radiation dose management market across varied regions) ・ Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the radiation dose management market ・ Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Bayer AG (Germany), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers AG (Germany), Sectra AB (Sweden), and FUJIFILM Holdings Corporation (Japan)

ページTOPに戻る

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 MARKET SCOPE 42
1.3.1 MARKETS COVERED 42
1.3.2 INCLUSIONS AND EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.4 CURRENCY CONSIDERED 45
1.5 STAKEHOLDERS 45
1.6 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 47
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 47
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 49
2.3 DISRUPTIVE TRENDS SHAPING MARKET 50
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 51
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 52
3 PREMIUM INSIGHTS 53
3.1 RADIATION DOSE MANAGEMENT MARKET OVERVIEW 53
3.2 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING
AND COUNTRY 54
3.3 RADIATION DOSE MANAGEMENT MARKET: REGIONAL GROWTH OPPORTUNITIES 55
4 MARKET OVERVIEW 56
4.1 INTRODUCTION 56
4.2 MARKET DYNAMICS 57
4.2.1 DRIVERS 57
4.2.1.1 Increasing utilization and complexity of imaging procedures 57
4.2.1.2 Increasing regulatory emphasis on dose monitoring, optimization, and reference levels 58
4.2.1.3 Growing concerns regarding radiation exposure and dose optimization 59
4.2.2 RESTRAINTS 59
4.2.2.1 High implementation and integration costs 59
4.2.2.2 Shortage of skilled professionals for radiation dose management and optimization 60
4.2.3 OPPORTUNITIES 61
4.2.3.1 Increasing adoption of AI-enabled radiation dose optimization 61
4.2.3.2 Growing adoption of vendor-neutral and cloud-based dose management platforms 61
4.2.3.3 Increasing focus on age-specific radiation dose optimization 62
4.2.4 CHALLENGES 62
4.2.4.1 Lack of standardized and interoperable dose data across modalities and systems 62
4.2.4.2 Variability in dose benchmarks and imaging protocols across institutions 63
4.3 UNMET NEEDS AND WHITE SPACES 64
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 64
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 65
5 INDUSTRY TRENDS 67
5.1 PORTER'S FIVE FORCES ANALYSIS 67
5.1.1 THREAT OF NEW ENTRANTS 68
5.1.2 THREAT OF SUBSTITUTES 68
5.1.3 BARGAINING POWER OF SUPPLIERS 69
5.1.4 BARGAINING POWER OF BUYERS 69
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.2 MACROECONOMIC INDICATORS 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS AND FORECAST 70
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 70
5.3 VALUE CHAIN ANALYSIS 70
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 72
5.3.2 DATA & KNOWLEDGE ASSETS 72
5.3.3 SOFTWARE & PLATFORM INFRASTRUCTURE 72
5.3.4 CLOUD SERVICE PROVIDERS 72
5.3.5 MARKETING & SALES 73
5.3.6 POST-SALES SERVICES 73
5.4 ECOSYSTEM ANALYSIS 73
5.5 PRICING ANALYSIS 75
5.5.1 INDICATIVE PRICE FOR RADIATION DOSE MANAGEMENT MARKET,
BY PRODUCT (2025) 76
5.5.2 INDICATIVE PRICE FOR RADIATION DOSE MANAGEMENT MARKET,
BY REGION (2025) 77
5.6 KEY CONFERENCES AND EVENTS 77
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
5.8 INVESTMENT AND FUNDING SCENARIO 80
5.9 CASE STUDY ANALYSIS 81
5.9.1 REDUCING CT DOSE THROUGH REAL-TIME DOSE MONITORING AND ALERTING 81
5.9.2 ESTABLISHING ENTERPRISE-WIDE, MULTI-MODALITY DOSE MANAGEMENT 81
5.9.3 REDUCED RADIATION DOSE IN SPECIALIST CANCER CARE 82
5.9.4 IMPROVED CARE COORDINATION 82
5.10 IMPACT OF US TARIFF OVERVIEW 83
5.10.1 INTRODUCTION 83
5.10.2 KEY TARIFF RATES 83
5.11 PRICE IMPACT ANALYSIS 84
5.12 IMPACT ON COUNTRY/REGION 85
5.12.1 US 85
5.12.2 EUROPE 85
5.12.3 ASIA PACIFIC 85
5.13 IMPACT ON END USERS 86
5.13.1 HOSPITALS AND HEALTHCARE SYSTEMS 86
5.13.2 DIAGNOSTIC AND IMAGING CENTERS 86
5.13.3 AMBULATORY SURGERY CENTERS 86
5.13.4 OTHER END USERS 87
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTION 88
6.1 KEY EMERGING TECHNOLOGIES 88
6.1.1 AI-ENABLED RADIATION DOSE PREDICTION, MONITORING, AND OPTIMIZATION 88
6.1.2 PATIENT-SPECIFIC AND PERSONALIZED DOSIMETRY TECHNOLOGIES 88
6.1.3 ADVANCED IMAGING TECHNOLOGIES FOR RADIATION DOSE OPTIMIZATION 89
6.2 COMPLEMENTARY TECHNOLOGIES 89
6.2.1 DICOM, RADIATION DOSE STRUCTURED REPORTS (RDSR), AND INTEROPERABILITY TECHNOLOGIES 89
6.2.2 CLOUD-BASED, VENDOR-NEUTRAL, AND ENTERPRISE DOSE MANAGEMENT ARCHITECTURES 90
6.2.3 DOSE REGISTRIES, BENCHMARKING, AND POPULATION-LEVEL
DOSE ANALYTICS 90
6.3 ADJACENT TECHNOLOGIES 91
6.3.1 COMPUTATIONAL DOSIMETRY AND PATIENT-SPECIFIC DOSE MODELING 91
6.4 TECHNOLOGY/PRODUCT ROADMAP 91
6.5 PATENT ANALYSIS 92
6.5.1 PATENT PUBLICATION TRENDS FOR RADIATION DOSE MANAGEMENT 92
6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 93
6.6 FUTURE APPLICATIONS 97
6.6.1 AI-ASSISTED PERSONALIZED RADIATION DOSE MANAGEMENT 97
6.6.2 REAL-TIME DOSE OPTIMIZATION AND INTELLIGENT IMAGING WORKFLOW AUTOMATION 97
6.6.3 LONGITUDINAL RADIATION-EXPOSURE MANAGEMENT AND PREDICTIVE DOSE ANALYTICS 98
6.7 IMPACT OF AI/GEN AI ON RADIATION DOSE MANAGEMENT MARKET 98
6.7.1 INTRODUCTION 98
6.7.2 POTENTIAL OF AI/GEN AI IN RADIATION DOSE MANAGEMENT MARKET 99
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 101
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 102
6.7.5 MEDICAL IMAGING EQUIPMENT & IMAGING INFORMATICS 102
6.7.6 DOSE REGISTRIES, BENCHMARKING & QUALITY MANAGEMENT 103
6.7.7 AI-ENABLED IMAGING & CLINICAL WORKFLOW 103
6.7.8 USER READINESS AND IMPACT ASSESSMENT 103
6.7.8.1 User readiness 103
6.7.8.1.1 User A: Hospitals & integrated health systems 104
6.7.8.1.2 User B: Practices outpatient diagnostic imaging centers & radiology practices 104
6.7.8.1.3 User C: Interventional radiology & cardiology centers 104
6.7.8.2 Impact assessment 105
6.7.8.2.1 User A: Hospitals & integrated health systems 105
6.7.8.2.1.1 Implementation 105
6.7.8.2.1.2 Impact 105
6.7.8.2.2 User B: Outpatient diagnostic imaging centers & radiology practices 106
6.7.8.2.2.1 Implementation 106
6.7.8.2.2.2 Impact 106
6.7.8.2.3 User C: Interventional radiology & cardiology centers 106
6.7.8.2.3.1 Implementation 106
6.7.8.2.3.2 Impact 107
7 REGULATORY LANDSCAPE 108
7.1 REGIONAL REGULATIONS AND COMPLIANCE 108
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
7.1.2 REGULATORY FRAMEWORK 116
7.1.2.1 North America 116
7.1.2.2 Europe 117
7.1.2.3 Asia Pacific 118
7.1.2.4 Latin America 119
7.1.2.5 Middle East & Africa 119
7.1.3 INDUSTRY STANDARDS 120
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 121
8.1 INTRODUCTION 121
8.2 DECISION-MAKING PROCESS 121
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 122
8.4 KEY STAKEHOLDERS IN BUYING PROCESS 122
8.4.1 KEY STAKEHOLDERS IN BUYING PROCESS 123
8.4.2 BUYING CRITERIA 123
8.5 ADOPTION BARRIERS & INTERNAL CHALLENGES 125
8.6 UNMET NEEDS FROM VARIOUS END USERS 125
8.6.1 UNMET NEEDS 126
8.6.2 END USER EXPECTATIONS 127
8.7 MARKET PROFITABILITY 128
9 RADIATION DOSE MANAGEMENT MARKET, BY OFFERING 129
9.1 INTRODUCTION 130
9.2 SOLUTIONS 130
9.2.1 GROWING ADOPTION OF INTEGRATED AND AUTOMATED RADIATION DOSE MANAGEMENT SOLUTIONS TO DRIVE MARKET 130
9.2.2 STANDALONE SOLUTIONS 132
9.2.2.1 Growing demand for flexible and cost-effective dose monitoring solutions to boost market 132
9.2.3 INTEGRATED SOLUTIONS 133
9.2.3.1 Growing need for enterprise-wide, multi-vendor dose management to propel market 133
9.3 SERVICES 134
9.3.1 GROWING NEED FOR SPECIALIZED IMPLEMENTATION, CONSULTING, AND TRAINING EXPERTISE TO BOOST MARKET 134
9.3.2 SUPPORT & MAINTENANCE SERVICES 136
9.3.2.1 Growing need for continuous system availability and software updates to boost market 136
9.3.3 IMPLEMENTATION & INTEGRATION SERVICES 137
9.3.3.1 Growing hospital networks to drive demand for implementation and integration services 137
9.3.4 CONSULTING SERVICES 138
9.3.4.1 Growing need to interpret dose trends and identify outliers to drive segment 138
9.3.5 EDUCATION & TRAINING SERVICES 139
9.3.5.1 Increasing need for skilled personnel to support radiation dose optimization to boost segment 139
10 RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION 140
10.1 INTRODUCTION 141
10.2 DOSE TRACKING & MONITORING 141
10.2.1 INCREASING ADOPTION OF AUTOMATED AND CONTINUOUS DOSE MONITORING 141
10.3 DOSE ANALYTICS & BENCHMARKING 142
10.3.1 GROWING NEED TO IDENTIFY DOSE OUTLIERS AND BENCHMARK IMAGING PERFORMANCE BOOSTS SEGMENT 142
10.4 DOSE REPORTING & REGULATORY COMPLIANCE 143
10.4.1 INCREASING REGULATORY EMPHASIS ON RADIATION DOSE DOCUMENTATION TO PROPEL SEGMENT 143
10.5 PROTOCOL & DOSE OPTIMIZATION 144
10.5.1 SEGMENT DRIVEN BY INCREASING FOCUS ON DOSE REDUCTION WHILE MAINTAINING DIAGNOSTIC IMAGE QUALITY 144
10.6 PATIENT RADIATION EXPOSURE MANAGEMENT 145
10.6.1 GROWING FOCUS ON PATIENT-SPECIFIC AND CUMULATIVE RADIATION EXPOSURE – KEY DRIVER 145
10.7 OTHER FUNCTIONS 146
10.7.1 INCREASING NEED FOR INTEROPERABILITY ACROSS HETEROGENEOUS IMAGING ENVIRONMENTS TO DRIVE SEGMENT 146
11 RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY 147
11.1 INTRODUCTION 148
11.2 AI-ENABLED TECHNOLOGY 148
11.2.1 GROWING ADOPTION OF AI DRIVES SEGMENT GROWTH 148
11.2.2 MACHINE LEARNING 149
11.2.2.1 Growing adoption of predictive and patient-specific dose optimization to boost segment 149
11.2.3 DEEP LEARNING 150
11.2.3.1 Increasing use of deep learning for automated imaging and dose optimization 150
11.2.4 COMPUTER VISION 151
11.2.4.1 Increasing automation of image analysis and anatomical assessment to drive segment 151
11.2.5 NATURAL LANGUAGE PROCESSING (NLP) 152
11.2.5.1 Increasing availability of unstructured clinical data – key driver 152
11.3 NON-AI/CONVENTIONAL TECHNOLOGY 153
11.3.1 ESTABLISHED CLINICAL ADOPTION AND REGULATORY RELIABILITY 153
12 RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL 154
12.1 INTRODUCTION 155
12.2 ON-PREMISE DEPLOYMENT 155
12.2.1 STRINGENT DATA-SECURITY POLICIES DRIVES SEGMENT GROWTH 155
12.3 CLOUD-BASED/WEB-BASED DEPLOYMENT 156
12.3.1 INCREASING NEED FOR SCALABLE, MULTI-SITE DOSE MONITORING AND REMOTE ACCESS TO IMAGING ANALYTICS BOOSTS DEMAND 156
13 RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL 158
13.1 INTRODUCTION 159
13.2 CAPITAL/ANNUAL PURCHASE MODEL 159
13.2.1 ESTABLISHED PROCUREMENT PRACTICES DRIVE DEMAND 159
13.3 PAY-PER-PROCEDURE MODEL 160
13.3.1 AFFORDABILITY DRIVES SEGMENT GROWTH 160
14 RADIATION DOSE MANAGEMENT MARKET, BY MODALITY 162
14.1 INTRODUCTION 163
14.2 COMPUTED TOMOGRAPHY (CT) 163
14.2.1 RAPID ADOPTION OF PHOTON-COUNTING CT AND AI-BASED RECONSTRUCTION TO DRIVE SEGMENT 163
14.3 FLUOROSCOPY & INTERVENTIONAL IMAGING 164
14.3.1 RISING PROCEDURAL COMPLEXITY INCREASES DEMAND FOR REAL-TIME RADIATION DOSE REDUCTION 164
14.4 RADIOGRAPHY 165
14.4.1 DIGITAL RADIOGRAPHY AND AI-BASED IMAGE ENHANCEMENT ENABLE LOWER EXPOSURE 165
14.5 MAMMOGRAPHY 166
14.5.1 EXPANSION OF 3D BREAST IMAGING DRIVES DEMAND 166
14.6 NUCLEAR MEDICINE 167
14.6.1 INCREASING USE OF HIGH-SENSITIVITY PET/SPECT AND AI-ENABLED RECONSTRUCTION TO DRIVE SEGMENT 167
14.6.2 PET 168
14.6.2.1 Higher PET sensitivity and AI reconstruction to boost demand 168
14.6.3 SPECT 169
14.6.3.1 Low-dose SPECT/CT technologies strengthen radiation optimization 169
14.6.4 HYBRID 169
14.6.4.1 Growing reliance on PET/CT and SPECT/CT drives market 169
15 RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION 171
15.1 INTRODUCTION 172
15.2 ONCOLOGY 172
15.2.1 INCREASING FOCUS ON ONCOLOGY DRIVES DEMAND 172
15.3 CARDIOLOGY 173
15.3.1 INCREASING USE IN CARDIOLOGY BOOSTS DEMAND 173
15.4 ORTHOPEDIC 174
15.4.1 HIGH COMPLEXITY OF PROCEDURES DRIVES DEMAND 174
15.5 DENTAL 175
15.5.1 GROWING USE OF CBCT PROPELS DEMAND 175
15.6 OTHER APPLICATIONS 176
15.6.1 NEED TO MANAGE REPEATED EXAMINATIONS DRIVES DEMAND 176
16 RADIATION DOSE MANAGEMENT MARKET, BY END USER 178
16.1 INTRODUCTION 179
16.2 HOSPITALS & HEALTHCARE SYSTEMS 179
16.2.1 DIVERSE IMAGING FLEETS DRIVE CENTRALIZED RDM AND PROTOCOL OPTIMIZATION ACROSS HOSPITAL NETWORKS 179
16.3 DIAGNOSTIC & IMAGING CENTERS 180
16.3.1 HIGH EXAMINATION VOLUMES AND MULTI-SITE IMAGING OPERATIONS ACCELERATE DEMAND 180
16.4 AMBULATORY CARE SETTINGS 181
16.4.1 EXPANSION OF OUTPATIENT AND AMBULATORY IMAGING INCREASES DEMAND 181
16.5 ACADEMIC & RESEARCH INSTITUTES 182
16.5.1 SEGMENT DRIVEN BY AI-DRIVEN LOW-DOSE IMAGING AND NEXT-GENERATION DOSE OPTIMIZATION TECHNOLOGIES 182
16.6 OTHER END USERS 183
16.6.1 REGULATORY OVERSIGHT, POPULATION-LEVEL RADIATION MONITORING, AND CLINICAL-TRIAL – KEY DRIVERS 183
17 RADIATION DOSE MANAGEMENT MARKET, BY REGION 185
17.1 INTRODUCTION 186
17.2 NORTH AMERICA 187
17.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 188
17.2.2 US 193
17.2.2.1 Regulatory focus on radiation safety drives market 193
17.2.3 CANADA 199
17.2.3.1 Increasing number of diagnostic imaging procedures to boost market 199
17.3 EUROPE 204
17.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 205
17.3.2 GERMANY 210
17.3.2.1 Rising diagnostic imaging demand and aging population to drive market 210
17.3.3 FRANCE 215
17.3.3.1 Healthcare modernization to accelerate radiation dose management adoption 215
17.3.4 UK 220
17.3.4.1 Rising imaging volumes and NHS digitalization to support market growth 220
17.3.5 ITALY 225
17.3.5.1 Regulatory emphasis on dose optimization and monitoring to propel market 225
17.3.6 SPAIN 229
17.3.6.1 Growing focus on patient dosimetry and radiation dose optimization to drive market 229
17.3.7 REST OF EUROPE 234
17.4 ASIA PACIFIC 240
17.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 241
17.4.2 CHINA 247
17.4.2.1 Largest patient pool and increased healthcare spending to aid market growth 247
17.4.3 JAPAN 252
17.4.3.1 Large and technologically advanced hospital infrastructure 252
17.4.4 INDIA 258
17.4.4.1 Favorable government policies and improved healthcare infrastructure to support market growth 258
17.4.5 AUSTRALIA 264
17.4.5.1 Advancement of national diagnostic reference levels to accelerate radiation dose optimization 264
17.4.6 SOUTH KOREA 270
17.4.6.1 Increasing medical imaging volumes and patient radiation exposure to boost market 270
17.4.7 REST OF ASIA PACIFIC 275
17.5 LATIN AMERICA 281
17.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 281
17.5.2 BRAZIL 287
17.5.2.1 Increasing regulatory focus and adoption of advanced imaging technologies to drive market 287
17.5.3 MEXICO 292
17.5.3.1 Rising demand for diagnostic imaging and adoption of lower-dose technologies to support market growth 292
17.5.4 REST OF LATIN AMERICA 297
17.6 MIDDLE EAST & AFRICA 302
17.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 303
17.6.2 GCC COUNTRIES 309
17.6.2.1 Saudi Arabia 315
17.6.2.1.1 Growing healthcare expenditure to boost market growth 315
17.6.2.2 UAE 320
17.6.2.2.1 Increasing healthcare infrastructure investments to drive market growth 320
17.6.2.3 Rest of GCC 326
17.6.3 SOUTH AFRICA 332
17.6.3.1 Increasing focus on radiation dose optimization to propel market growth 332
17.6.4 REST OF MIDDLE EAST & AFRICA 337
18 COMPETITIVE LANDSCAPE 342
18.1 OVERVIEW 342
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 342
18.3 REVENUE ANALYSIS, 2021-2025 347
18.4 MARKET SHARE ANALYSIS, 2021–2025 347
18.5 BRAND COMPARISON 351
18.6 COMPANY VALUATION AND FINANCIAL METRICS 352
18.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 353
18.7.1 STARS 353
18.7.2 EMERGING LEADERS 353
18.7.3 PERVASIVE PLAYERS 353
18.7.4 PARTICIPANTS 354
18.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 355
18.7.5.1 Company footprint 355
18.7.5.2 Region footprint 356
18.7.5.3 Offering footprint 357
18.7.5.4 Deployment model footprint 358
18.7.5.5 Technology footprint 359
18.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 360
18.8.1 PROGRESSIVE COMPANIES 360
18.8.2 RESPONSIVE COMPANIES 360
18.8.3 DYNAMIC COMPANIES 360
18.8.4 STARTING BLOCKS 360
18.8.5 COMPETITIVE BENCHMARKING STARTUPS/SMES, 2025 362
18.9 COMPETITIVE SCENARIO 363
18.9.1 DEALS 366
18.9.2 OTHER DEVELOPMENTS 370
19 COMPANY PROFILES 372
19.1 KEY PLAYERS 372
19.1.1 BAYER AG 372
19.1.1.1 Products/solutions/services offered 374
19.1.1.2 Recent developments 374
19.1.1.2.1 Product launches & upgrades 374
19.1.1.2.2 Deals 375
19.1.1.2.3 Other developments 376
19.1.1.3 MnM view 376
19.1.1.3.1 Key strengths 376
19.1.1.3.2 Strategic choices 376
19.1.1.3.3 Weaknesses and competitive threats 377
19.1.2 SIEMENS HEALTHINEERS AG 378
19.1.2.1 Business overview 378
19.1.2.2 Products/solutions/services offered 380
19.1.2.3 Recent developments 381
19.1.2.3.1 Product launches & upgrades 381
19.1.2.3.2 Deals 382
19.1.2.3.3 Expansions 384
19.1.2.4 MnM view 385
19.1.2.4.1 Key strengths 385
19.1.2.4.2 Strategic choices 385
19.1.2.4.3 Weaknesses and competitive threats 385
19.1.3 KONINKLIJKE PHILIPS N.V. 386
19.1.3.1 Business overview 386
19.1.3.2 Products/solutions/services offered 388
19.1.3.3 Recent developments 389
19.1.3.3.1 Product launches & upgrades 389
19.1.3.3.2 Deals 390
19.1.3.4 MnM view 390
19.1.3.4.1 Key strengths 390
19.1.3.4.2 Strategic choices 391
19.1.3.4.3 Weaknesses and competitive threats 391
19.1.4 GE HEALTHCARE 392
19.1.4.1 Business overview 392
19.1.4.2 Products/solutions/services offered 394
19.1.4.3 Recent developments 395
19.1.4.3.1 Product launches & upgrades 395
19.1.4.3.2 Deals 396
19.1.4.3.3 Other developments 398
19.1.4.4 MnM view 398
19.1.4.4.1 Key strengths 398
19.1.4.4.2 Strategic choices 399
19.1.4.4.3 Weaknesses and competitive threats 399
19.1.5 FUJIFILM HOLDINGS CORPORATION 400
19.1.5.1 Business overview 400
19.1.5.2 Products/solutions/services offered 402
19.1.5.3 Recent developments 402
19.1.5.3.1 Product launches & upgrades 402
19.1.5.3.2 Deals 403
19.1.5.3.3 Other developments 404
19.1.5.4 MnM view 404
19.1.5.4.1 Key strengths 404
19.1.5.4.2 Strategic choices 404
19.1.5.4.3 Weaknesses and competitive threats 405
19.1.6 SECTRA AB 406
19.1.6.1 Business overview 406
19.1.6.2 Products/solutions/services offered 407
19.1.6.3 Recent developments 408
19.1.6.3.1 Product launches & upgrades 408
19.1.6.3.2 Deals 408
19.1.6.3.3 Other developments 409
19.1.7 CANON INC. 410
19.1.7.1 Business overview 410
19.1.7.2 Products/solutions/services offered 411
19.1.7.3 Recent developments 412
19.1.7.3.1 Product launches & upgrades 412
19.1.7.3.2 Deals 413
19.1.7.3.3 Other developments 414
19.1.8 AGFA-GEVAERT N.V. 415
19.1.8.1 Business overview 415
19.1.8.2 Products/solutions/services offered 416
19.1.8.3 Recent developments 417
19.1.8.3.1 Product launches & upgrades 417
19.1.8.3.2 Deals 418
19.1.9 PACSHEALTH, LLC 419
19.1.9.1 Business overview 419
19.1.9.2 Products/solutions/services offered 420
19.1.9.3 Recent developments 420
19.1.9.3.1 Deals 420
19.1.10 QAELUM 421
19.1.10.1 Business overview 421
19.1.10.2 Products/solutions/services offered 422
19.1.10.3 Recent developments 422
19.1.10.3.1 Deals 422
19.1.11 MEDSQUARE 424
19.1.11.1 Business overview 424
19.1.11.2 Products/solutions/services offered 425
19.1.11.3 Recent developments 425
19.1.11.3.1 Product launches & upgrades 425
19.1.11.3.2 Deals 426
19.1.12 NOVARAD 427
19.1.12.1 Business overview 427
19.1.12.2 Products/solutions/services offered 428
19.1.13 INFINITT HEALTHCARE CO., LTD. 429
19.1.13.1 Business overview 429
19.1.13.2 Products/solutions/services offered 430
19.1.14 CARESTREAM HEALTH 431
19.1.14.1 Business overview 431
19.1.14.2 Products/solutions/services offered 432
19.1.14.3 Recent developments 433
19.1.14.3.1 Product Launches & upgrades 433
19.1.14.3.2 Deals 434
19.1.15 SHIMADZU CORPORATION 436
19.1.15.1 Business overview 436
19.1.15.2 Products/solutions/services offered 437
19.1.15.3 Recent developments 438
19.1.15.3.1 Products launches & upgrades 438
19.1.15.3.2 Deals 439
19.1.16 NANJING PERLOVE MEDICAL EQUIPMENT CO., LTD. 440
19.1.16.1 Business overview 440
19.1.16.2 Products/solutions/services offered 441
19.1.16.3 Recent developments 442
19.1.16.3.1 Product Launches & upgrades 442
19.1.16.3.2 Deals 442
19.1.17 NEUSOFT MEDICAL SYSTEMS CO., LTD. 444
19.1.17.1 Business overview 444
19.1.17.2 Products/solutions/services offered 445
19.1.17.3 Recent developments 446
19.1.17.3.1 Product launches & upgrades 446
19.1.17.3.2 Deals 447
19.1.18 KONICA MINOLTA, INC 448
19.1.18.1 Business overview 448
19.1.18.2 Products/solutions/services offered 449
19.1.18.3 Recent developments 450
19.1.18.3.1 Product Launches & upgrades 450
19.1.18.3.2 Deals 451
19.1.19 IBA 452
19.1.19.1 Business overview 452
19.1.19.2 Products/solutions/services offered 454
19.1.19.3 Recent developments 455
19.1.19.3.1 Product launches & upgrades 455
19.1.19.3.2 Deals 455
19.1.20 LUNIT INC. 457
19.1.20.1 Business overview 457
19.1.20.2 Products/solutions/services offered 458
19.1.20.3 Recent developments 459
19.1.20.3.1 Deals 459
19.2 OTHER PLAYERS 460
19.2.1 QIT SYSTEME GMBH 460
19.2.2 IMALOGIX 460
19.2.3 IDOSE 461
19.2.4 MYXRAYDOSE LTD. 461
19.2.5 VIRTUAL PHANTOMS INC. 462
20 RESEARCH METHODOLOGY 463
20.1 RESEARCH APPROACH 463
20.1.1 SECONDARY RESEARCH 464
20.1.1.1 Key data from secondary sources 465
20.1.2 PRIMARY RESEARCH 465
20.1.2.1 Key data from primary sources 467
20.1.2.2 Insights from primary experts 468
20.2 RESEARCH METHODOLOGY 469
20.3 MARKET SIZE ESTIMATION 471
20.4 MARKET BREAKDOWN DATA TRIANGULATION 476
20.5 MARKET SHARE ESTIMATION 477
20.6 STUDY ASSUMPTIONS 477
20.7 LIMITATIONS 478
20.7.1 SCOPE-RELATED LIMITATIONS 478
20.7.2 METHODOLOGY-RELATED LIMITATIONS 478
20.8 RISK ASSESSMENT 478
21 APPENDIX 479
21.1 DISCUSSION GUIDE 479
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 485
21.3 CUSTOMIZATION OPTIONS 487
21.4 RELATED REPORTS 487
21.5 AUTHOR DETAILS 488

ページTOPに戻る

List of Tables/Graphs

TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD 45.
TABLE 2 RADIATION DOSE MANAGEMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 68.
TABLE 3 RADIATION DOSE MANAGEMENT MARKET: ROLE IN ECOSYSTEM 74.
TABLE 4 INDICATIVE PRICE FOR RADIATION DOSE MANAGEMENT MARKET, BY OFFERING (2025) 76.
TABLE 5 INDICATIVE PRICE FOR RADIATION DOSE MANAGEMENT MARKET, BY REGION (2025) 77.
TABLE 6 RADIATION DOSE MANAGEMENT: KEY CONFERENCES AND EVENTS (2026–2027) 78.
TABLE 7 CASE 1: REDUCING RADIATION DOSE THROUGH DOSE MONITORING AND ALERTS 81.
TABLE 8 CASE 2: ESTABLISHING MULTI-MODALITY DOSE MANAGEMENT THROUGH RADIMETRICS 81.
TABLE 9 CASE 3: REDUCING RADIATION DOSE THROUGH DOSE MANAGEMENT AND PROTOCOL OPTIMIZATION 82.
TABLE 10 CASE 4: ASKLEPIOS CLINICS — ENTERPRISE-WIDE RADIATION DOSE MANAGEMENT 82.
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 83.
TABLE 12 TOP APPLICANT COUNTRIES FOR RADIATION DOSE MANAGEMENT MARKET 94.
TABLE 13 RADIATION DOSE MANAGEMENT MARKET: KEY PATENTS 96.
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109.
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110.
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 112.
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114.
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115.
TABLE 19 REGULATORY SCENARIO IN NORTH AMERICA 116.
TABLE 20 REGULATORY SCENARIO IN EUROPE 117.
TABLE 21 REGULATORY SCENARIO IN ASIA PACIFIC 118.
TABLE 22 REGULATORY SCENARIO IN LATIN AMERICA 119.
TABLE 23 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA 119.
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%) 123.
TABLE 25 BUYING CRITERIA FOR TOP THREE END USERS 124.
TABLE 26 UNMET NEEDS IN RADIATION DOSE MANAGEMENT MARKET 126.
TABLE 27 END USER EXPECTATIONS IN RADIATION DOSE MANAGEMENT MARKET 127.
TABLE 28 RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 130.
TABLE 29 SOLUTIONS OFFERED BY KEY MARKET PLAYERS 131.
TABLE 30 RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 131.
TABLE 31 RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 132.
TABLE 32 KEY STANDALONE SOLUTIONS OFFERED BY MARKET PLAYERS 133.
TABLE 33 RADIATION DOSE MANAGEMENT MARKET FOR STANDALONE SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 133.
TABLE 34 KEY INTEGRATED SOLUTIONS OFFERED BY MARKET PLAYERS 134.
TABLE 35 RADIATION DOSE MANAGEMENT MARKET FOR INTEGRATED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 36 SERVICES OFFERED BY KEY MARKET PLAYERS 135.
TABLE 37 RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 135.
TABLE 38 RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 39 RADIATION DOSE MANAGEMENT MARKET FOR SUPPORT & MAINTENANCE SERVICES, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 40 RADIATION DOSE MANAGEMENT MARKET FOR IMPLEMENTATION & INTEGRATION SERVICES, BY REGION, 2024–2031 (USD MILLION) 138.
TABLE 41 RADIATION DOSE MANAGEMENT MARKET FOR CONSULTING SERVICES, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 42 RADIATION DOSE MANAGEMENT MARKET FOR EDUCATION & TRAINING SERVICES, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 43 RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 141.
TABLE 44 RADIATION DOSE MANAGEMENT MARKET FOR DOSE TRACKING & MONITORING, BY REGION, 2024–2031 (USD MILLION) 142.
TABLE 45 RADIATION DOSE MANAGEMENT MARKET FOR DOSE ANALYTICS & BENCHMARKING, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 46 RADIATION DOSE MANAGEMENT MARKET FOR DOSE REPORTING & REGULATORY COMPLIANCE, BY REGION, 2024–2031 (USD MILLION) 144.
TABLE 47 RADIATION DOSE MANAGEMENT MARKET FOR PROTOCOL & DOSE OPTIMIZATION, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 48 RADIATION DOSE MANAGEMENT MARKET FOR PATIENT RADIATION EXPOSURE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 49 RADIATION DOSE MANAGEMENT MARKET FOR OTHER FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 50 RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 148.
TABLE 51 RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 149.
TABLE 52 RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 149.
TABLE 53 RADIATION DOSE MANAGEMENT MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION) 150.
TABLE 54 RADIATION DOSE MANAGEMENT MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION) 151.
TABLE 55 RADIATION DOSE MANAGEMENT MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 56 RADIATION DOSE MANAGEMENT MARKET FOR NATURAL LANGUAGE PROCESSING (NLP), BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 57 RADIATION DOSE MANAGEMENT MARKET FOR NON-AI/CONVENTIONAL TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 153.
TABLE 58 RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 155.
TABLE 59 RADIATION DOSE MANAGEMENT MARKET FOR ON-PREMISE DEPLOYMENT, BY REGION, 2024–2031 (USD MILLION) 156.
TABLE 60 RADIATION DOSE MANAGEMENT MARKET FOR CLOUD-BASED/WEB-BASED DEPLOYMENT, BY REGION, 2024–2031 (USD MILLION) 157.
TABLE 61 RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 159.
TABLE 62 RADIATION DOSE MANAGEMENT MARKET FOR CAPITAL/ANNUAL PURCHASE MODEL, BY REGION, 2024–2031 (USD MILLION) 160.
TABLE 63 RADIATION DOSE MANAGEMENT MARKET FOR PAY-PER-PROCEDURE MODEL, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 64 RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 163.
TABLE 65 RADIATION DOSE MANAGEMENT MARKET FOR COMPUTED TOMOGRAPHY (CT), BY REGION, 2024–2031 (USD MILLION) 164.
TABLE 66 RADIATION DOSE MANAGEMENT MARKET FOR FLUOROSCOPY & INTERVENTIONAL IMAGING, BY REGION, 2024–2031 (USD MILLION) 165.
TABLE 67 RADIATION DOSE MANAGEMENT MARKET FOR RADIOGRAPHY, BY REGION, 2024–2031 (USD MILLION) 166.
TABLE 68 RADIATION DOSE MANAGEMENT MARKET FOR MAMMOGRAPHY, BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 69 RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 167.
TABLE 70 RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY REGION, 2024–2031 (USD MILLION) 168.
TABLE 71 RADIATION DOSE MANAGEMENT MARKET FOR PET, BY REGION, 2024–2031 (USD MILLION) 168.
TABLE 72 RADIATION DOSE MANAGEMENT MARKET FOR SPECT, BY REGION, 2024–2031 (USD MILLION) 169.
TABLE 73 RADIATION DOSE MANAGEMENT MARKET FOR HYBRID, BY REGION, 2024–2031 (USD MILLION) 170.
TABLE 74 RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 172.
TABLE 75 RADIATION DOSE MANAGEMENT MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 173.
TABLE 76 RADIATION DOSE MANAGEMENT MARKET FOR CARDIOLOGY, BY REGION, 2024–2031 (USD MILLION) 174.
TABLE 77 RADIATION DOSE MANAGEMENT MARKET FOR ORTHOPEDICS, BY REGION, 2024–2031 (USD MILLION) 175.
TABLE 78 RADIATION DOSE MANAGEMENT MARKET FOR DENTAL, BY REGION, 2024–2031 (USD MILLION) 176.
TABLE 79 RADIATION DOSE MANAGEMENT MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 177.
TABLE 80 RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 179.
TABLE 81 RADIATION DOSE MANAGEMENT MARKET FOR HOSPITALS & HEALTHCARE SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 180.
TABLE 82 RADIATION DOSE MANAGEMENT MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2024–2031 (USD MILLION) 181.
TABLE 83 RADIATION DOSE MANAGEMENT MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION) 182.
TABLE 84 RADIATION DOSE MANAGEMENT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 183.
TABLE 85 RADIATION DOSE MANAGEMENT MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 184.
TABLE 86 RADIATION DOSE MANAGEMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 186.
TABLE 87 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 88 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 189.
TABLE 89 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 189.
TABLE 90 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 190.
TABLE 91 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 190.
TABLE 92 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 191.
TABLE 93 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 191.
TABLE 94 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 191.
TABLE 95 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 192.
TABLE 96 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 192.
TABLE 97 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 192.
TABLE 98 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 193.
TABLE 99 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 193.
TABLE 100 US: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 194.
TABLE 101 US: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 195.
TABLE 102 US: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 195.
TABLE 103 US: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 196.
TABLE 104 US: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 196.
TABLE 105 US: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 106 US: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 197.
TABLE 107 US: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 197.
TABLE 108 US: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 198.
TABLE 109 US: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 198.
TABLE 110 US: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198.
TABLE 111 US: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 199.
TABLE 112 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 200.
TABLE 113 CANADA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 200.
TABLE 114 CANADA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 200.
TABLE 115 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 201.
TABLE 116 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201.
TABLE 117 CANADA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 202.
TABLE 118 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 202.
TABLE 119 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 202.
TABLE 120 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 203.
TABLE 121 CANADA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 203.
TABLE 122 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 203.
TABLE 123 CANADA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 204.
TABLE 124 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 125 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 206.
TABLE 126 EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 206.
TABLE 127 EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 206.
TABLE 128 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 207.
TABLE 129 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 207.
TABLE 130 EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 131 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 208.
TABLE 132 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 208.
TABLE 133 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 209.
TABLE 134 EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 209.
TABLE 135 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 209.
TABLE 136 EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 210.
TABLE 137 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 211.
TABLE 138 GERMANY: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 211.
TABLE 139 GERMANY: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 211.
TABLE 140 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 212.
TABLE 141 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 212.
TABLE 142 GERMANY: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 213.
TABLE 143 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 213.
TABLE 144 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 213.
TABLE 145 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 214.
TABLE 146 GERMANY: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 214.
TABLE 147 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 214.
TABLE 148 GERMANY: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 215.
TABLE 149 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 216.
TABLE 150 FRANCE: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 216.
TABLE 151 FRANCE: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 216.
TABLE 152 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 217.
TABLE 153 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 217.
TABLE 154 FRANCE: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 218.
TABLE 155 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 218.
TABLE 156 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 218.
TABLE 157 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 219.
TABLE 158 FRANCE: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 219.
TABLE 159 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 219.
TABLE 160 FRANCE: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 220.
TABLE 161 UK: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 221.
TABLE 162 UK: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 163 UK: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 164 UK: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 222.
TABLE 165 UK: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222.
TABLE 166 UK: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 222.
TABLE 167 UK: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 223.
TABLE 168 UK: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 223.
TABLE 169 UK: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 223.
TABLE 170 UK: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 224.
TABLE 171 UK: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 224.
TABLE 172 UK: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 224.
TABLE 173 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 225.
TABLE 174 ITALY: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 225.
TABLE 175 ITALY: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 226.
TABLE 176 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 226.
TABLE 177 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 227.
TABLE 178 ITALY: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 227.
TABLE 179 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 227.
TABLE 180 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 228.
TABLE 181 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 228.
TABLE 182 ITALY: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 228.
TABLE 183 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 229.
TABLE 184 ITALY: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 229.
TABLE 185 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 230.
TABLE 186 SPAIN: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 230.
TABLE 187 SPAIN: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 231.
TABLE 188 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 231.
TABLE 189 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 232.
TABLE 190 SPAIN: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 232.
TABLE 191 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 232.
TABLE 192 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 233.
TABLE 193 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 233.
TABLE 194 SPAIN: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 233.
TABLE 195 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 234.
TABLE 196 SPAIN: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 234.
TABLE 197 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 235.
TABLE 198 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 235.
TABLE 199 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 236.
TABLE 200 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 236.
TABLE 201 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 237.
TABLE 202 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 237.
TABLE 203 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 237.
TABLE 204 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 238.
TABLE 205 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 238.
TABLE 206 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 238.
TABLE 207 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239.
TABLE 208 REST OF EUROPE: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 239.
TABLE 209 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241.
TABLE 210 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 242.
TABLE 211 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 242.
TABLE 212 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 242.
TABLE 213 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 243.
TABLE 214 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 243.
TABLE 215 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 244.
TABLE 216 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 244.
TABLE 217 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 244.
TABLE 218 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 245.
TABLE 219 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 245.
TABLE 220 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246.
TABLE 221 ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 246.
TABLE 222 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 247.
TABLE 223 CHINA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 224 CHINA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 225 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 249.
TABLE 226 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 249.
TABLE 227 CHINA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 250.
TABLE 228 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 250.
TABLE 229 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 250.
TABLE 230 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 251.
TABLE 231 CHINA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 251.
TABLE 232 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252.
TABLE 233 CHINA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 252.
TABLE 234 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 253.
TABLE 235 JAPAN: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 253.
TABLE 236 JAPAN: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 237 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 254.
TABLE 238 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 255.
TABLE 239 JAPAN: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 255.
TABLE 240 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 255.
TABLE 241 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 256.
TABLE 242 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 256.
TABLE 243 JAPAN: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 256.
TABLE 244 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257.
TABLE 245 JAPAN: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 257.
TABLE 246 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 258.
TABLE 247 INDIA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 259.
TABLE 248 INDIA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 259.
TABLE 249 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 260.
TABLE 250 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 260.
TABLE 251 INDIA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 261.
TABLE 252 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 261.
TABLE 253 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 261.
TABLE 254 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 262.
TABLE 255 INDIA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 262.
TABLE 256 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263.
TABLE 257 INDIA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 263.
TABLE 258 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 264.
TABLE 259 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 265.
TABLE 260 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 265.
TABLE 261 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 266.
TABLE 262 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266.
TABLE 263 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 267.
TABLE 264 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 267.
TABLE 265 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 267.
TABLE 266 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 268.
TABLE 267 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 268.
TABLE 268 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 269.
TABLE 269 AUSTRALIA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 269.
TABLE 270 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 271.
TABLE 271 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 271.
TABLE 272 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 271.
TABLE 273 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 272.
TABLE 274 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 272.
TABLE 275 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 273.
TABLE 276 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 273.
TABLE 277 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 273.
TABLE 278 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 274.
TABLE 279 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 274.
TABLE 280 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 275.
TABLE 281 SOUTH KOREA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 275.
TABLE 282 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 276.
TABLE 283 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 276.
TABLE 284 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 277.
TABLE 285 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 277.
TABLE 286 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 278.
TABLE 287 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 278.
TABLE 288 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 278.
TABLE 289 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 279.
TABLE 290 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 279.
TABLE 291 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 279.
TABLE 292 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 280.
TABLE 293 REST OF ASIA PACIFIC: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 280.
TABLE 294 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282.
TABLE 295 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 282.
TABLE 296 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 282.
TABLE 297 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 283.
TABLE 298 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 283.
TABLE 299 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 284.
TABLE 300 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 284.
TABLE 301 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 284.
TABLE 302 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 285.
TABLE 303 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 285.
TABLE 304 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 285.
TABLE 305 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 286.
TABLE 306 LATIN AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 286.
TABLE 307 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 288.
TABLE 308 BRAZIL: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 288.
TABLE 309 BRAZIL: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 288.
TABLE 310 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 289.
TABLE 311 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 289.
TABLE 312 BRAZIL: RADIATION DOSE MANAGEMENT MARKET FOR AI-ENABLED TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION) 290.
TABLE 313 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 290.
TABLE 314 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 290.
TABLE 315 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY MODALITY, 2024–2031 (USD MILLION) 291.
TABLE 316 BRAZIL: RADIATION DOSE MANAGEMENT MARKET FOR NUCLEAR MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 291.
TABLE 317 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 291.
TABLE 318 BRAZIL: RADIATION DOSE MANAGEMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 292.
TABLE 319 MEXICO: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING, 2024–2031 (USD MILLION) 293.
TABLE 320 MEXICO: RADIATION DOSE MANAGEMENT MARKET FOR SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 293.
TABLE 321 MEXICO: RADIATION DOSE MANAGEMENT MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 293.
TABLE 322 MEXICO: RADIATION DOSE MANAGEMENT MARKET, BY